CombiGene publishes EU Growth Prospectus relating to the rights issue
The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such publication or distribution would violate applicable laws or regulations. See the section “Important information” at the end of this press release.
The board of directors of CombiGene AB (publ) (“CombiGene”) has prepared an EU Growth Prospectus relating to the fully guaranteed rights issue that was made public by CombiGene on 8 March 2021. The EU Growth Prospectus has today been approved by and registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).
The EU Growth Prospectus, containing the full terms and conditions, and application forms are available on CombiGene’s website, https://www.combigene.com. The EU Growth Prospectus will also be available on the Swedish Financial Supervisory Authority’s website, http://www.fi.se.
Summary of the rights issue
- The rights issue will, if fully subscribed, provide the company with approximately SEK 75 million before issue costs.
- The net proceeds will, among other things, be used to finance the final parts of CombiGene’s preclinical program for CG01 and initiated in vivo studies in the lipodystrophy project CGT2.
- The rights issue is covered by subscription undertakings corresponding to approximately 12 per cent of the rights issue, and guarantee undertakings corresponding to approximately 88 per cent of the rights issue.
- Existing shareholders in CombiGene will receive eight (8) subscription rights for each share and eleven (11) subscription rights entitle the holder to subscribe for one (1) new share.
Timetable for the rights issue
Record date for receiving subscription rights
15 March 2021
Trading in subscription rights
17-26 March 2021
17-31 March 2021
Press release of outcome
Around 6 April 2021
Vator Securities AB is financial adviser and Advokatfirmaet Schjødt AS, filial is legal adviser to CombiGene in connection with the rights issue. Hagberg & Aneborn Fondkommission AB is issuing agent in connection with the rights issue.
For more information:
Bert Junno, chairman of the board of directors
Tel: +46(0) 70 7 77 22 09
Jan Nilsson, CEO
Tel: +46 (0)704 66 31 63
The information was provided by the below contact person for publication on 15 March 2021 at 11.15 CET.
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in CombiGene.
This press release may not be released, published or distributed, directly or indirectly, in or into USA, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where participation would require additional prospectuses, registration or measures besides those required by Swedish law. Nor may this press release be distributed in or into such countries or any other country or jurisdiction in which distribution requires such measures or otherwise would be in conflict with applicable regulations. Any failure to comply with the restrictions described may result in a violation of applicable securities regulations.
No subscription rights, paid subscription shares (Sw. Betalda tecknade aktier) or shares issued by CombiGene have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act“) or the securities legislation of any state or other jurisdiction of the United States and no subscription rights, paid subscription shares or shares may be offered, subscribed for, exercised, pledged, sold, resold, granted, delivered or otherwise transferred, directly or indirectly, in or into the United States. There will be no public offering of such securities in the United States. The securities referred to herein have not been approved or disapproved by the U.S. Securities and Exchange Commission (SEC), any state securities commission or other regulatory authority in the United States, nor have any of the foregoing authorities passed upon or endorsed the merits of the rights issue or the accuracy or adequacy of this announcement. Any representation to the contrary is a criminal offence in the United States.
This press release contains certain forward-looking information that reflects CombiGene’s present view of future events as well as financial and operational development. Words such as “intend”, “assess”, “expect”, “may”, “plan”, “believe”, “estimate” and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.